The only online resource covering the emerging psychedelic medicine sector with a focus on informing and updating the European Investor community. We aim to educate and inform with latest company and sector news, interviews and developments in this nascent but fast—moving sector, with the potential to disrupt and transform mental healthcare.
Psychedelics, when used wisely, have the potential to heal us, help inspire us, and perhaps even save us
Mental health problems are one of the main causes of the overall disease burden worldwide. Mental health and behavioural problems (eg depression, anxiety, alcohol and drug addiction) are reported to be the primary drivers of disability worldwide. Up to a third of people with depression (more than 264 million people worldwide according to the WHO) are failed even after multiple treatment attempts.
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — The McQuade Center for Strategic Research and Development, LLC (MSRD), a member
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming
Ended the year with strong cash position of $59.2 million Revenues grew 81% year-over-year to $0.5 million for Q4 2021 Revenues grew 72%
